http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109564225-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-153 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6875 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2017-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109564225-B |
| titleOfInvention | Histone and/or proADM as markers for indicating adverse events |
| abstract | The present invention relates to the diagnosis, prognosis, risk assessment and/or risk stratification of adverse events, in particular death, in a subject. The present invention relates to a method comprising determining the level of at least one histone, in particular histone H2B, H4, H2A and/or H3, in a sample of said subject, and wherein the level of said at least one histone is indicative of said adverse event of said subject; and/or determining the level of proadrenomedullin (proADM) in a sample of said subject, and wherein said level of proADM is indicative of said adverse event in said subject. The invention also relates to kits for carrying out the methods of the invention. |
| priorityDate | 2016-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 975.